A Tiny Eye Implant Can Restore Reading Vision. Europe Has Approved It

A 2 millimetre retinal implant paired with camera-equipped glasses has crossed an important line between experiment and medical product. Europe has authorized PRIMA for commercial use in people who have lost central vision to advanced age-related macular degeneration.

KEY NUMBER
In the multicentre trial, 84% of the 38 participants reported that they could identify letters, numbers or words using the prosthetic vision system.

What Europe has approved

Science Corporation says PRIMA has received a CE mark under the European Union Medical Device Regulation. The authorization covers people with geographic atrophy, an advanced form of age-related macular degeneration that destroys light-sensitive cells in the centre of the retina.

Central vision is what people use to read, recognize faces and inspect fine detail. Peripheral vision may remain, but the missing centre can severely reduce independence. Existing treatments can sometimes slow certain forms of the disease, yet they cannot rebuild photoreceptors that have already been lost.

PRIMA does not regenerate those cells. It creates an electronic route around the damaged area, producing a form of artificial central vision that works alongside the patient's remaining natural peripheral sight.

How the electronic eye works

The system combines a tiny photovoltaic chip implanted beneath the damaged central retina with specialized glasses. A camera on the glasses captures the scene ahead and a processor converts it into a simplified image. The glasses then project patterned near-infrared light toward the implant.

The implant converts that light into electrical stimulation. Surviving retinal cells relay the signal through the visual pathway to the brain, where the patient learns to interpret the resulting patterns. Because the implant is photovoltaic, it receives information and power through the projected light rather than a wire crossing the eye.

The glasses can magnify text, an important feature because the reconstructed image is not equivalent to ordinary sharp vision. Training and practice are part of using the system, much as a person must learn to interpret another sensory aid.

What patients actually gained

The clinical evidence published in the New England Journal of Medicine involved 38 patients treated at 17 sites in five countries. After 12 months, the company reports a mean improvement of 25.5 letters, a little more than five lines on a standard eye chart, when participants used prosthetic vision.

Eighty percent achieved an improvement of at least 10 letters, and 84% reported being able to recognize letters, numbers or words. Importantly, the implant was placed under the atrophic central retina without a decline in average pre-existing natural vision.

Those numbers are meaningful because the participants had irreversible damage. Still, “restored vision” needs context. PRIMA does not recreate the colour, resolution or effortless field of view of a healthy eye. Its practical value is narrower: recovering enough central detail for tasks such as reading enlarged text and recognizing shapes.

Why the approval matters

Brain-computer interfaces often appear in demonstrations or small experimental trials. PRIMA is notable because it has moved into regulated commercial availability in Europe. Science Corporation describes it as the first CE-marked interface for restoring detailed form vision.

The company is activating clinical sites and seeking country-level reimbursement. Germany is expected to be among the first markets, with an initial commercial procedure potentially taking place in September. In the United States, PRIMA has received FDA Breakthrough Device and Humanitarian Use Device designations, but it is still investigational and has not received US marketing approval.

The milestone may also help establish practical infrastructure for visual prostheses: surgical training, rehabilitation, device servicing, reimbursement and long-term follow-up. Those systems are as important to real adoption as the chip itself.

What happens next

The immediate test is whether approval becomes genuine access. Hospitals need trained teams, insurers or national health systems must decide what they will cover, and patients need realistic guidance about who is likely to benefit.

Science Corporation is also developing a newer chip and less cumbersome glasses. Better resolution, a wider useful field and smaller external equipment could make later generations more practical, but those improvements will need their own evidence.

The takeaway

PRIMA does not give patients a normal eye, and it does not cure macular degeneration. It does something more specific and still remarkable: it converts images into signals that a damaged visual system can use to recover selected central tasks. European approval now moves the technology from a promising trial toward the harder test of everyday medicine.